Challenges in hemophilia care in Australia and New Zealand

Current Medical Research and Opinion

Volumn 31, Issue 11, 2015, Pages 1985-1991

  Brown, S A ^a,b   Phillips, J ^c   Barnes, C ^d   Curtin, J ^e   Mcrae, S ^f   Ockelford, P ^g   Rowell, J ^h   Smith, M P ⁱ   Dunkley, S ^j  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b Pathology Queensland   (Australia)

^c WELLINGTON HOSPITAL   (New Zealand)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^f ROYAL ADELAIDE HOSPITAL   (Australia)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

more..

Author keywords

Benchmarking; Comprehensive healthcare; Demography; Health expenditures; Hemophilia; Outcome assessment

Indexed keywords

AGING; ARTHRALGIA; ARTHROPATHY; AUSTRALIA; COMORBIDITY; CONSENSUS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEMOPHILIA; HUMAN; LIFE EXPECTANCY; NEW ZEALAND; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; REVIEW; TELEHEALTH; TRANSITION TO ADULT CARE; ADULT; CHILD; HEMOPHILIA A; PEDIATRICS;

ADULT; AUSTRALIA; CHILD; CONSENSUS; HEMOPHILIA A; HUMANS; NEW ZEALAND; PEDIATRICS; TRANSITION TO ADULT CARE;

EID: 84947496201     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1082990     Document Type: Review

References (53)

1. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012; 88: 329-35
2. Duncan N, Shapiro A, Ye X, et al. Treatment patterns, health related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia 2012; 18: 760-5
3. Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia 1990-2007. Haemophilia 2010; 16: 437-46
4. Darby SC, Kan SW, Spooner SJ, et al. Mortality, life expectancy and causes of death in people with haemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25
5. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. (Treatment Guidelines Working Group on behalf of the World Federation of Hemophilia). Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47
6. Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, et al. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia 2012; 18: e91-4
7. Stonebraker JS, Bolton-Maggs PH, Soucie JM, et al. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32
8. Fransen van de Putte DE, Fischer K, Pulles AE, et al. Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients. Thromb Res 2012; 130: 157-62
9. Mannucci PM, Schutgens REG, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with haemophilia. Blood 2009; 114: 5256-63
10. Philipp C. The aging patient with hemophilia: complications, comorbidities, and management issues. Hematology ASH Education Book 2010; 1: 191-6
11. Stephensen D, Rodriguez-Merchan EC. Orthopaedic co-morbidities in the elderly haemophilia population: a review. Haemophilia 2013; 19: 166-73
12. Lee C, Dusheiko G. The natural history and antiviral treatment of hepatitis C in haemophilia. Haemophilia 2002; 8: 322-9
13. Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. Haemophilia 2006; 12 (Suppl 3): 13-21
14. Australian Bleeding Disorders Registry (ABDR) Annual Report 2012-13. National Blood Authority. Available at: http://www.blood.gov.au/data-Analysis-reporting. Accessed June 2014
15. Young G. New challenges in haemophilia: long-Derm outcomes and complications. Hematology ASH Education Book 2012; 1: 362-8
16. Petrini P, Seuser A. Haemophilia care in adolescents-compliance and lifestyle issues. Haemophilia 2009; 15 (Suppl 1): 15-19
17. Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013; 4: 49-56
18. Australian Government Department of Health and Ageing. Telehealth Technical Standards Position Paper v0.93. Australian Government Department of Health and Ageing, August 2012. ISBN: 978-1-74241-561-1. Publications Approval Number-D0542
19. Hofstede FG, Fijnvandraat K, Plug I, et al. Haemophilia 2008;14:1035-8
20. Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica 2013; 98: 1481-6
21. Collins PW, Bjorkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75
22. Bolton-Maggs PHB. Optimal haemophilia care versus the reality. Br J Haematol 2005; 132: 671-82
23. Lee M, Morfini M, Schulman S, Ingerslev J; and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Scientific and Standardization Committee Communication. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. Posted on the ISTH Website 21 March 2001. Available at: http://www.isth.org/members/group.aspx?id=100348. Accessed July 2014
24. Barnes C. Importance of pharmacokinetics in the management of hemophilia. Pediatr Blood Cancer 2013; 60: S27-9
25. Berntorp E. Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study. Haemophilia 2013; 19: 805-7
26. Dargaud Y, Negrier C. Individually tailored prophylaxis in patients with severe hemophilia. J Coagul Disord 2010; 2: 11-17
27. Young G, Sorensen B, Dargaud Y, et al. Thrombin generation and whole blood viscoelastic assays in the management of haemophilia: current status of the art and future perspectives. Blood 2013; 121: 1944-50
28. Ceponis A, Wong-Sefidan I, Glass CS, von Drygalski A. Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients. Haemophilia 2013; 19: 790-8
29. dYoung I, Young L, Brasser M, Ockelford P. Chronic arthropathy management in haemophilia: assessing the impact of a new model of care. N Z Med J 2012; 125: 161-3
30. Powell A. A review of changing pain management strategies over the last decade in an adult Australian haemophilia centre [Abstract]. Haemophilia 2014; 20 (Suppl 3): 69
31. Schneider P, Farahati J, Reiners C. Radiosynovectomy in rheumatology, orthopedics and hemophilia. J Nucl Med 2005; 46: 48S-54
32. Young G, Tachdjian R, Baumann K, Panopoulos G. Comprehensive management of chronic pain in haemophilia. Haemophilia 2014; 20: e113-20
33. Raffini L, Manno C. Modern management of haemophilic arthropathy. Br J Haematol 2007; 136: 777-87
34. Coppola A, Cerbone AM, Mancuso G, et al. Confronting the psychological burden of haemophilia. Haemophilia 2001; 17: 21-7
35. Penica S, Williams KE. The use of a psychological intervention to increase adherence during factor administration in a child with haemophilia. Haemophilia 2008; 14: 939-44
36. dYoung AI, Young L, Ockelford PA, et al. The use of a co-design model in improving timely bleed reporting by adults with haemophilia living in the Auckland region of New Zealand. Haemophilia 2014; 20: 388-97
37. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308: 1452-9
38. Brown SA, Barnes C, Curtin J, et al. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Intern Med J 2012; 42: 1243-50
39. Auerswald G, Morfini M. Prophylaxis with recombinant activated Factor VII in hemophilia patients with inhibitors. J Coagul Disord 2010; 2: 1-8
40. Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010; 16 (Suppl 2): 16-23
41. Young G, Auerswald G, Jimenez-Yuste V, et al. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 2011; 17: e849-57
42. Escobar MA. Health economics in haemophilia: a review from the clinicians perspective. Haemophilia 2010; 16 (Suppl 3): 29-34
43. Lyseng-Williamson KA, Plosker GL. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 2007; 25: 1007-29
44. Hay JW, Zhou ZY. Economical comparison of APCC vs. rFVIIa for mild-Do-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia 2011; 17: e969-74
45. Kubisz P, Plamenova I, Stasko J, et al. Long-Derm secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report. Thromb Haemost 2010; 103: 868-70
46. Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92
47. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-Associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-65
48. Fischer K, Hermans C.; on behalf of the European Haemophilia Therapy Standardisation Board (EHTSB). The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. Haemophilia 2013; 19: 35-43
49. Fischer K, Steen Carlsson K, Petrini P, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129-36
50. Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorbidity 2011; 1: 51-9
51. Martinoli C, Alberighi ODC, Di Minno G, et al. Development and definition of a simplified scanning procedure and scoring method for haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109: 1170-9
52. Doria AS, Keshava SN, Mohanta A, et al. Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation. Am J Reoentgenol 2015; 204: W336-47
53. Keshava SN, Gibikote SV, Mohanta A, et al. Ultrasound and magnetic resonance imaging of healthy paediatric ankles and knees: a baseline for comparison with haemophilic joints. Haemophilia 2015; 21: e210-22